why choose us

First received: February 08, 2023

Clinical Trial: TRUDI: TDXD+Durva in HER2+/Low IBC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Invasive Breast Cancer

Study Type: INTERVENTIONAL


Official Title: TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer

Brief Summary: The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer.The names of the study drugs involved in this study are:Trastuzumab deruxtecanDurvalumab

Read more